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Abstract
Background: More accurate methods of prognostication are likely to lead to improvements in the quality of care
of patients approaching the ends of their lives. The Prognosis in Palliative care Scales (PiPS) are prognostic models
of survival. The scores are calculated using simple clinical data and observations. There are two separate PiPS
models; PiPS-A for patients without blood test results and PiPS-B for patients with blood test results. Both models
predict whether a patient is likely to live for “days”, “weeks” or “months” and have been shown to perform as well
as clinicians’ estimates of survival. PiPS-B has also been found to be significantly better than doctors’ estimates of
survival. We report here a protocol for the validation of PiPS and for the evaluation of the accuracy of other
prognostic tools in a new, larger cohort of patients with advanced cancer.
Methods: This is a national, multi-centre, prospective, observational cohort study, aiming to recruit 1778 patients
via palliative care services across England and Wales. Eligible patients have advanced, incurable cancer and have
recently been referred to palliative care services. Patients with or without capacity are included in the study.
The primary outcome is the accuracy of PiPS predictions and the difference in accuracy between these predictions
and the clinicians’ estimates of survival; with PiPS-B being the main model of interest. The secondary outcomes
include the accuracy of predictions by the Palliative Prognostic Index (PPI), Palliative Performance Scale (PPS),
Palliative Prognostic score (PaP) and the Feliu Prognostic Nomogram (FPN) compared with actual patient survival
and clinicians’ estimates of survival.
A nested qualitative sub-study using face-to-face interviews with patients, carers and clinicians is also being undertaken
to assess the acceptability of the prognostic models and to identify barriers and facilitators to clinical use.
Discussion: The study closed to recruitment at the end of April 2018 having exceeded the required sample size of
1778 patients. The qualitative sub-study is nearing completion. This demonstrates the feasibility of recruiting large
numbers of participants to a prospective palliative care study.
Trial registration: ISRCTN13688211 (registration date: 28/06/2016).
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Background
Patients approaching the ends of their lives, their rela-
tives and clinicians all value accurate prognostic infor-
mation [1–5]. This information is routinely provided by
clinicians using their clinical intuition. However, clini-
cians’ estimates of survival (CES) are often inaccurate
and over-optimistic [6]. The need for more accurate
methods of prognostication was highlighted by the
Neuberger report [7] into the short-comings of the
implementation of the Liverpool Care Pathway [8].
Determining more accurately how long patients with
advanced cancer have left to live would enable both pa-
tients and their relatives to make plans for their future
[3]. It would also aid clinicians to target treatments to
those patients most likely to benefit and it would safe-
guard other patients from receiving treatments that they
are unlikely to benefit from [9]. Prognostic information
may help clinicians to plan services and to ensure that
patients are cared for in the most appropriate environ-
ment. More reliable prognostic estimates may also facili-
tate the identification of patients for inclusion on
palliative care registers [10] and the prioritisation of pa-
tients who are referred to palliative care services.
The Prognosis in Palliative care Scales (PiPS) are pre-
dictive models of survival and were previously developed
by members of our research team in order to provide an
objective aid to clinicians’ intuition [9]. The original
study recruited prospectively a cohort of 1018 patients
with advanced cancer, who were no longer undergoing
disease-modifying treatment. This was a multi-centre
study involving 18 specialist palliative care services
across England. Separate prognostic models were created
for patients without (PiPS-A) or with (PiPS-B) available
blood test results. The PiPS scores were able to predict
whether a patient was likely to live for “days” (less than
14 days), “weeks” (between 2 and 7 weeks) or “months”
(2 months or longer). These categories were chosen as
they seemed to have the greatest face validity among cli-
nicians. Both PiPS models were shown to perform as
well as CES. The PiPS-B prognostic estimate was found
to be significantly better than doctors’ prognostic esti-
mates. Before recommending PiPS for use in routine
clinical practice, it is important to check that the models
provide accurate and reliable estimates of survival in a
new group of patients.
More recently, two research studies have published
validation data about the PiPS models [11, 12] in differ-
ent clinical settings. Baba and colleagues (2015) [11]
undertook an independent validation of the PiPS models
in Japanese cancer patients and reported that the PiPS
instrument performed as well as in Gwilliam’s original
study [9]. However, the Japanese study did not compare
the accuracy of PiPS to the accuracy of CES. Differences
in cancer epidemiology and oncology practice between
Japan and UK may also be a relevant consideration. The
study by Kim and co-workers (2014) [12] reported that
the PiPS instruments performed approximately as well
as in the original study. However, the Kim study in-
cluded a relatively small number of participants and the
study population was restricted to palliative cancer pa-
tients in a specialist cancer hospital in South Korea. No
large scale validation has yet been undertaken in the UK.
Taken together, these two studies strengthen the case
for undertaking a large-scale validation study in the UK
using CES as a comparator. Based on systematic reviews
[13, 14], four other prognostic models have been identified
that might also be useful in clinical practice and which are
in need of further evaluation. These are the Palliative
Prognostic Index (PPI) [15], the Palliative Performance
Scale (PPS) [16], the Palliative Prognostic (PaP) [17] score
and the Feliu Prognostic Nomogram (FPN) [18].
The PPI and the PPS can both be calculated without
the need for a blood test (like PiPS-A). The PPI model
stratifies patients into three groups; survival shorter
than 3 weeks; shorter than 6 weeks; or more than
6 weeks [15]. The PPI has shown a high accuracy level
in patients with short estimates of survival [19]. The
PPS is a measure of functional status and is one of the
variables included in the PPI score. Although not spe-
cifically designed as a prognostic instrument, and there-
fore lacking some face validity as a stand-alone
prognostic tool, the PPS has been found to have prog-
nostic significance in patients with advanced disease
[20, 21]. Using data from large observational studies,
the PPS can be used to predict the probability of dying
across a range of survival times [20].
The PaP and the FPN, both require blood test results
(like PiPS-B). The PaP score classifies patients into three
risk groups based on a 30-day survival probability of less
than 30%; between 30 and 70%; and more than 70% [17].
There is increasing evidence to support its validity in a
variety of settings [22–26]. The total PaP score was
shown in one study to be more accurate than a simple
clinician prediction of survival [27]. One practical con-
cern with the PaP score is that it relies on CES. This can
make the PaP challenging to use when clinicians are un-
sure about survival times or when an “objective” esti-
mate is required that is free from the influence of CES.
The FPN predicts survival at 15, 30 and 60 days [18]. In
one study the FPN was found to be more accurate than
the PaP [18] and does not rely on subjective CES.
The PiPS2 study was designed with the overall aim of
validating the accuracy of the PiPS-A and PiPS-B [9].
The primary objectives of the study are: to validate the
PiPS models and; to compare the performance of
PiPS-B against CES. The secondary objectives are to
validate other selected prognostic models (PPI, PPS,
PaP and FPN).
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A nested qualitative sub-study has also been embed-
ded in the PiPS2 study to assess the acceptability of the
prognostic models to patients, carers and clinicians and
to identify barriers and facilitators to clinical use. This is
particularly relevant because in clinical practice it is
often the relatives and carers of non-competent or
semi-conscious patients who most wish to have access
to accurate prognostic information.
Methods
Study design
This is a multi-centre, prospective, observational, cohort
study to validate various prognostic models in patients
with advanced, incurable cancer. The study involves pa-
tients from 28 palliative care services across England
and UK and is sponsored by University College London.
Patients were recruited in three palliative care settings:
a) community palliative care teams (including day
hospice and palliative care outpatients)
b) hospital palliative care teams
c) inpatient palliative care units
The planned recruitment period for the validation study
was from August 2016 to the end in April 2018. At least
three months after all recruitment has ended, a list of
study participants will be sent to the Health and Social
Care Information Centre (HSCIC) in order to determine
dates of death. The accuracy of the studied prognostic
models will then be compared against actual survival.
Following Medical Research Council Guidance [28] a
subset of patients who agreed to participate in the main
study, their next-of-kin (informal carers), patients who
declined to participate in the main study, and health care
professionals, were recruited into a nested qualitative
sub-study to explore views about prognostication and
the use of prognostic tools.
Participants
The study involved both patients with or without cap-
acity to consent to participate. Many patients at the end
of their lives become confused, semi-conscious, and co-
matose or may have pre-existing cognitive impairment,
they therefore frequently lack capacity to consent to par-
ticipate in research. The inclusion of patients who lack
capacity is therefore of great importance as the study
population should be representative of those patients
commonly seen in palliative care services. Capacity was
assessed by the attending clinician using the Department
of Health guidance [29]. If capacity was in doubt, the
clinician carried out a capacity test as provided by the
Royal College of General Practitioners’ Mental Capacity
Act Toolkit for Adults in England and Wales 2011 [30].
Inclusion criteria
a) Patients with locally advanced or metastatic incurable
cancer. A patient with incurable cancer has an
estimated prognosis of survival of less than one year.
b) Men and women aged 18 years or over.
c) Patients who had recently been referred to palliative
care services. Recent referral has various meanings
across different palliative care settings. For a
community, day hospice or palliative care
outpatient, “recent” means that the patient should
have had fewer than three previous contacts with
the palliative care service before they are recruited
to the study. For inpatient palliative care patients
(including hospital support teams), “recent” referral
means that the patient should have been first seen
by a member of the palliative care team no more
than 7-days previously. The date of referral was
considered the date the patient had first been seen
by a member of the relevant palliative care team.
d) Sufficient English language skills for patients with
capacity to read and understand the Patient
Information Sheet and undertake study
assessments.
Exclusion criterion
Patients receiving (or planned to receive) treatment with
curative intent at the time of consent. Patients receiving
palliative treatment were still eligible to participate.
Study assessments
Data were collected at a single time point and were usu-
ally obtained from a review of the medical notes or from a
discussion with clinical staff. If patients were able to re-
spond to questions data might have partly been obtained
directly from them. The data that were required for the
calculation of each prognostic score are shown in Table 1.
Demographic, disease and treatment related data and
capacity recording
Demographic details of enrolled patients, such as age,
gender and current patients’ location (e.g., home, hos-
pital, hospice) were recorded. National Health Service
(NHS) number and date of birth were also recorded to
be sent to the HSCIC. Information on the nature and
site of primary tumour and sites of metastases (if any)
were also collected. Additionally, patients’ capacity to
consent to participate in the study was documented.
Key symptoms
The presence or the absence of key symptoms was re-
corded (this was required for the scoring of the prognos-
tic models); anorexia, dysphagia, dyspnoea, fatigue and
weight loss.
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Abbreviated mental health score
This is a test that assesses cognitive function [31]. This
test is not applicable to patients without capacity, who
were attributed scores of zero.
Clinical assessments
Clinical assessments included:
1. Recording of the presence or the absence of ascites,
peripheral oedema, delirium and decreased oral intake.
Pulse rate was also measured over one minute.
2. The Eastern Co-operative Oncology Group (ECOG)
performance status [32]. This is a measurement of
patients’ level of everyday functioning.
3. A 7-point scale of observer-rated health status. The
scores range from very poor (point 1) to excellent
(point 7).
4. The Karnofsky Performance Scale (KPS) [33] this is
used to assess patients’ functional impairment.
5. The PPS [16]. This is one of the prognostic models
that this study aims to validate. It describes the
patients’ current ambulatory level; activity level and
Table 1 Data required for the calculation of prognostic models
Variable Prognostic model
PiPS-A PiPS-B PPI PPSa PaP FPN
ECOG performance status X X X
General health status X X
Abbreviated Mental Test Score > 3 X X
Primary breast cancer X
Primary prostate cancer X X
Distant metastases (any) X X
Liver metastases X
Bone metastases X X
Anorexia X X X
Dysphagia X
Dyspnoea X X X
Weight loss in last month X
Pulse rate X X
Fatigue X
PPSa score X X
Oral intake X
Oedema X
Delirium X
CES X
KPS X
Time to terminal diseaseb X
Blood Results:
White blood count X X
Lymphocyte count X X X
Neutrophil count X
Platelet count X
Urea X
Albumin X X
Alkaline phosphatase X
Alanine transaminase X
C-Reactive protein X
Lactate dehydrogenase X
aDespite PPS being designed as a measure of functional status, it does have prognostic significance and was therefore included in the prognostic
models this study intends to validate. PPS is listed in both “Variable” and “Prognostic Model” sections as it is one of the variables used for the
calculation of the PPI score bTime to terminal disease refers to the time between the initial cancer diagnosis and the date at which the cancer became
incurable (i.e., time at which deemed to be inoperable or became metastatic)
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extent of disease; self-care abilities; intake and con-
scious level.
6. Estimation of the time to terminal disease by the
clinicians. This is defined as the time elapsed between
the diagnosis and development of incurable disease
and is required to calculate the FPN.
Blood test results
For patients with capacity a fresh blood specimen must
have been taken. For patients without capacity there was
no requirement to take a fresh blood specimen, however if
a blood sample was being taken for another reason as a
part of routine clinical care within 72 h of study enrolment
then the relevant tests were requested. Even if no new spe-
cimen was being taken from a patient without capacity, if
relevant results were available within 72 h of being en-
rolled in the study then these results were recorded.
The blood test results required are: white blood count,
lymphocyte count, neutrophil count, platelet count,
urea, albumin, alkaline phosphatase, alanine transamin-
ase, C-reactive protein, lactate dehydrogenase. Blood
specimens were processed locally in the routine clinical
laboratory using usual arrangements.
Clinicians’ estimates of survival
The attending doctor and nurse estimated survival of study
participants independently. When the estimates agreed
then this represented the combined multi-professional pre-
diction. When they were discordant, the doctor and nurse
discussed the case and reached a consensus. In order to
characterise the prognosticators in more detail they were
asked to provide information about themselves (i.e., age,
gender, professional training and years of specialist experi-
ence). Clinicians were also asked to provide their prognostic
estimates using a number of different formats in order to
facilitate comparison with the outputs of the prognostic
scores. Clinicians were asked: to provide approximate esti-
mates of length of survival - “days” (0–13 days); “weeks”
(2–7 weeks); “months+” (2 months or longer); to provide
more specific estimates of survival to the nearest week
(from < 1 week to > 12 weeks); to estimate the probability
of survival at specific time points (1 day; 3 days; 7 days;
15 days; 30 days and 60 days).
Data management
A study database for the storage, management and ana-
lyses of identifiable data has been developed via a secure
web application named “REDCap” (Research Electronic
Data Capture) and using the UCL Data Safe Haven se-
cure system. This system has been certified to the
ISO27001 information security standard and conforms
to the NHS Information Governance Toolkit (http://
www.ucl.ac.uk/isd/itforslms/services/handling-sens-data/
tech-soln).
The rest of the (non-identifiable) study data have been
sent to a separate database (i.e., electronic Case Report
Form - eCRF) that has been created and supported by a
company called “Sealed Envelope” (https://www.sealeden-
velope.com/). Data from the paper CRFs have manually
been transferred to the eCRFs by the researchers at each
participating site.
A data monitoring plan has also been put in place to
ensure optimal data quality across sites.
Recruitment procedure
Patients’ identification
In each participating service, members of the clinical
team maintained a screening log of all new referrals to
the service. For the patients who were not eligible to
participate, the screening log records the following infor-
mation: age range, gender, reason for ineligibility.
Consent procedure
Study procedures differed between patients with and
without capacity.
Patients with capacity Eligible patients were approached
by a member of the clinical team about participation in
the study. If eligible patients were not approached by a
team member then the reason for failure to do so was
recorded on the screening log.
Potential participants who had been approached by a
member of the clinical team were asked if they are be
willing to speak to a member of the research team and
are handed a Patient Information Sheet (PIS). A member
of the research team then discussed the study with the
patient and sought their consent to participate. For com-
munity patients this discussion might have occurred
over the telephone. Written informed consent was usu-
ally obtained at least 24 h after the PIS had been handed
out but could have been obtained on the same day if it
was more convenient and acceptable for the patient to
do so. If the patient declined to participate in the study
then the reason for this (if known) was documented on
the screening log.
Patients without capacity For patients without capacity
a personal consultee was sought for advice. For patients
with no personal consultee, the advice of a nominated
consultee was sought. The nominated consultee was
usually another doctor working in the hospital/hospice
(who was not involved in the research), a social worker,
a chaplain or the patient’s General Practitioner (GP).
In a similar manner to the approach adopted for pa-
tients with capacity, consultees of patients without cap-
acity were advised that it was usual practice to wait for
24 h before giving assent. If the consultee gave telephone
advice for the patient to be included in the study but
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they are unable to visit the unit to provide written evi-
dence of assent then verbal agreement was initially
deemed to be sufficient to allow the research team to
enrol the patient in the study and start data collection.
However, in these circumstances an assent form was
posted to the consultee to be signed and returned to the
research team within two weeks of the patient being en-
rolled in the study. If no signed assent form was received
then the patient was withdrawn from the study and all
data were destroyed.
Patients with fluctuating capacity Patients who tem-
porarily lacked and then recovered capacity were informed
about their involvement in the study and have the oppor-
tunity to withdraw or confirm participation [9].
Outcome measures
Primary outcome measures
The survival of patients (measured from the date pa-
tients consented to participate), the CES and the predic-
tions of the PiPS-A and the PiPS-B prognostic models.
Secondary outcome measures
The predictions produced by the PPI, PPS, PaP and
FPN.
Sample size
The sample size calculations are based on data collected
during the original study [9].
For the comparison between PiPS-B model predictions and CES
PiPS-B is the primary model of interest for this research.
To show at least a 5% improvement in correct predic-
tions using PiPS-B compared to clinicians’ predictions,
assuming 80% power and 5% significance level and using
a McNemar’s test, a total of 1267 patients will be re-
quired. The formula and the software used for these cal-
culations are based on the work produced by Machin
and co-workers (2009) [34]. It is estimated that in order
to obtain 1267 complete data sets it is be necessary to
recruit 1334 patients with capacity (assuming 5% miss-
ing data). In order to recruit 1334 patients with capacity
it is be necessary to recruit 1778 patients in total
(assuming 25% of patients will lack capacity).
For the validation of the PiPS models
To validate predictions from a risk model it has been
recommended that the validation data should have at
least 100 events [35]. The validation data for the pro-
posed study will involve several centres. There is no
guidance on sample size calculation for multi-centre val-
idation data. We expect clustering of patients within
centres to be minimal based on other studies in commu-
nity care [36]. However, to be conservative we have
inflated the number of events required in the validation
data to 150. Assuming an event rate of 17.8%, based on
the original study, we will require 843 patients to valid-
ate the PiPS-B model. In fact, 1778 patients will be re-
cruited, most of who will be able to provide data for the
validation of both PiPS-A and PiPS-B, thus this sample
size will be more than adequate to validate both models.
Using similar arguments, the proposed sample size will
also be more than sufficient to simply validate the other
prognostic models (i.e., PPI, PPS, PaP and FPN).
Planned analyses
Descriptive analysis
Predictors and outcomes will be summarised using descrip-
tive analysis. Categorical predictors will be reported as raw
numbers and percentages. Continuous variables will be
summarised using mean or median and standard deviation
or interquartile (IQ) range as appropriate. The percentage
of values missing for each predictor will also be presented.
The survival times of patients will be summarised using
median and IQ ranges, and Kaplan Meier graphs.
Primary analyses
Validation of PiPS models (comparison between PiPS
model predictions and actual patients’ survival) The
PiPS models will be validated as they were presented for
use in the original study by Gwilliam and co-workers [9].
For both PiPS-A and PiPS-B, two separate models have
been developed to predict the two week (14 day) and two
month (56 day) survival of patients, thus, generating three
prognostic categories i.e., less than two weeks, two weeks
to two months and greater than two months.
The discriminatory ability of the models will be
assessed using the C-statistic. Separate C-statistics will
be calculated for the “two weeks” and the “two months”
models. The PiPS online calculator provides (see
www.pips.sgul.ac.uk) a prediction as to whether a patient
will survive for “days”, “weeks” or “months”. Model
performance will also be assessed by plotting Kaplan-Meier
survival curves for each of the three risk groups identified
by the PiPs models (“days,” “weeks,” and “months+”). The
model calibration will be assessed by comparing observed
and predicted probabilities [37].
Comparison between PiPS-B model predictions and
CES To compare the accuracy of the model predictions
and CES, the primary analysis will focus on the PiPS-B
model. McNemar’s test will be used to compare the pro-
portion of overall patient deaths predicted correctly by
PIPS-B with the corresponding proportion predicted
correctly by clinicians.
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Secondary analyses
As part of the secondary analyses the PiPS models’ predic-
tions for the two week and two month cut-off points will
be combined to produce a categorical prediction of sur-
vival (“days,” “weeks,” or “months/years”) and will be com-
pared with clinicians’ estimates and the corresponding
observed values descriptively with respect to their accur-
acy. Linear weighted k will also be used to compare the
performance of the clinicians with that of the models.
The PPI, PPS, PaP and FPN prognostic models will also
be assessed as a part of the secondary analyses. The calibra-
tion of these prognostic models will be assessed using the
calibration slope [37] based on a logistic model for binary
outcomes and Cox model for survival outcomes [38].
Graphical comparisons of the observed and predicted risks
for clinically relevant patient risk groups will also be made.
Clinically relevant time points will be used for comparisons
for survival outcomes. Model discrimination will be
assessed using the C-statistic for binary outcomes and
C-index for survival outcomes [39]. The performance mea-
sures estimated for the various models will be compared
descriptively. The predictions made by these prognostic
models will also be compared with the corresponding ob-
served outcomes and clinician predictions (where available).
Bias due to missing data will be investigated and multiple
imputation based on chained equations [40] will be used to
impute missing predictor values if considered necessary.
Interim results – Patient recruitment
Recruitment started in August 2016 and the required sam-
ple size was reached by the end April 2018 (see Fig. 1).
Nested qualitative sub-study
Semi-structured, face to face interviews were conducted
with a purposive sample of approximately 15 patients,
15 carers and 15 clinicians to determine the acceptability
of using prognostic indicators, and barriers and facilita-
tors to clinicians’ use. Data saturation will determine the
final sample sizes, which may be larger or smaller than
anticipated. To date, 28 patients, 19 carers and 32 clini-
cians were enrolled in the qualitative sub-study.
Interviews were audio recorded, and used iterative topic
guides based on reviews of the literature, themes arising
from preceding interviews, and the MORECare recommen-
dations for conducting research at the end of life [41] The
patient and carer interviews explored whether participants
wish to know the patient’s prognosis, and if so whether they
would have preferred clinicians’ estimates of survival or
prognostic modelling. Those wishing to know their progno-
sis were asked how this information should have been pre-
sented to them. Interviews were of 30–60 min duration to
ensure that participants were not overburdened.
The clinician interviews were interactive and explored
the acceptability of PiPS, PPI, PPS, PAP and FPN. Partici-
pants were shown the prognostic models, and commented
Fig. 1 PiPS2 recruitment chart
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on their utility. Topic guides included questions about po-
tential barriers and facilitators to using the models, and to
discussing prognostic information with patients and
carers. Interviews were of 60 min duration to allow
enough time for in-depth discussion.
Interview data will be entered into NVivo 10.0
(https://www.qsrinternational.com/nvivo/) and analysed
using the five stages of Framework Analysis [42]: famil-
iarisation, developing a thematic framework, indexing,
charting, and mapping and interpretation.
Discussion
This study recruited the required sample size of 1778
patients across England and Wales by the end of April
2018. These data demonstrate that recruitment to a
multi-centre prospective palliative care study is achievable.
The results of this study, should permit a recommenda-
tion to be made about the accuracy of a variety of prog-
nostic models, and whether or not the PiPS-B model is
significantly better than a multi-professional MDT esti-
mate of survival. In addition to this quantitative validation
study, an embedded qualitative sub-study is also being
undertaken. This is designed to assess the acceptability of
the different prognostic models to patients, carers and cli-
nicians and to make an assessment of the barriers to clin-
ical use. We anticipate that the overall results of our
research are expected to remain relevant and important to
the needs of the NHS in the future as the number of pa-
tients with advanced cancer is anticipated to increase sub-
stantially over the next twenty years.
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